NCT06240520View on ClinicalTrials.gov

Optimizing Reversal of HIV Latency With Combination Therapy

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

October 31, 2025

Conditions
Hiv
Interventions
DRUG

Panobinostat 20 MG Oral Capsule

Panobinostat 20mg will be administered once orally

DRUG

Pyrimethamine 200mg Oral Tablet

Pyrimethamine 200mg will be administered once orally

DRUG

Lenalidomide 25 MG Oral Capsule

Lenalidomide 25mg will be administered once orally

Trial Locations (3)

3015 GD

Erasmus Medical Centre, Rotterdam

Unknown

Amsterdam University Medical Center, Amsterdam

University Medical Center Utrecht, Utrecht

Sponsors
All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

AIDSfonds

UNKNOWN

lead

Erasmus Medical Center

OTHER